Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 13;12(9):1424.
doi: 10.3390/life12091424.

Renessans Helps in Early Clearance of SARS-CoV-2: In-Vivo Activity of the Iodine Complex in Rhesus macaque

Muhammad Nawaz  1 , Muhammad Adnan Ashraf  1 , Muhammad Asad Ali  1 , Muhammad Zubair Shabbir  1 , Muhammad Abu Bakr Shabbir  1 , Imran Altaf  1 , Sohail Raza  1 , Saira Rafique  1 , Sohail Hassan  1 , Nageen Sardar  1 , Adnan Mehmood  1 , Muhammad Waqar Aziz  1 , Sehar Fazal  1 , Muhammad Tahir Khan  1 , Hafiz Muhammad Moavia Atique  1 , Ali Asif  1 , Zia Ullah  2 , Mubashir Iqbal  1 , Talha Imtiaz  1 , Muhammad Anwar  1 , Nadia Mukhtar  1 , Tahir Yaqub  1
Affiliations

Renessans Helps in Early Clearance of SARS-CoV-2: In-Vivo Activity of the Iodine Complex in Rhesus macaque

Muhammad Nawaz et al. Life (Basel). .

Abstract

Iodine complexes have known antimicrobial properties along with reported in-vitro antiviral activity for several viruses. Renessans is one such product with iodine complexes and ascorbic acid. The present study was designed to determine its efficacy for SARS-CoV-2 in Rhesus macaque. Rhesus macaque were assigned to: A) prophylactic group (n = 3), (B) treatment group (n = 3), (C) infection control group (n = 4), and (D) negative control group (n = 4). Groups A, B, and C were challenged with 2 × 106 TCID of SARS-CoV-2. The prophylactic group (A) was administered Renessans from 5 days before infection till 8 days postinfection (DPI). The treatment group (B) was administered Renessans from 3 till 8 DPI. Group C was administered water-insoluble fractions only. Nasal swabs from all monkeys of groups A, B, and C remained positive for SARS-CoV-2 till 2 and 7 DPI, while the swabs became negative for groups A and B at 14 DPI. Likewise, fecal matter of monkeys in group A returned negative results during the experiment, while that of group B had significantly decreased viral load (101.5 genome copies/mL) compared to group C (103 genome copies/mL). Hence, it is concluded that Renessans has in-vivo SARS-CoV-2 activity and may result in early clearance of SARS-CoV-2.

Keywords: COVID-19; animal trial; antiviral; coronavirus; iodine compound.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Detailed timeline of events for determining the in-vivo efficacy of the antiviral drug (Renessans) for SARS-CoV-2.
Figure 2
Figure 2
Longitudinal comparison of average fecal viral load of experimental and control groups.
Figure 3
Figure 3
Graphical representation of the comparison of average nasal viral load of experimental and control groups. ***: p < 0.01, ns: non-significant.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lake M.A. What We Know so Far: COVID-19 Current Clinical Knowledge and Research. Clin. Med. 2020;20:124. doi: 10.7861/clinmed.2019-coron. - DOI - PMC - PubMed
    1. WHO Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-NCoV) [(accessed on 18 August 2020)]. Available online: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-...
    1. Worldometer Coronavirus Cases. [(accessed on 18 July 2020)]. Available online: https://www.worldometers.info/coronavirus/
    1. Wang X., Cao R., Zhang H., Liu J., Xu M., Hu H., Li Y., Zhao L., Li W., Sun X., et al. The Anti-Influenza Virus Drug, Arbidol Is an Efficient Inhibitor of SARS-CoV-2 in Vitro. Cell Discov. 2020;6:4–8. doi: 10.1038/s41421-020-0169-8. - DOI - PMC - PubMed
    1. Zheng Y.-Y., Ma Y.-T., Zhang J.-Y., Xie X. COVID-19 and the Cardiovascular System. Nat. Rev. Cardiol. 2020;17:259–260. doi: 10.1038/s41569-020-0360-5. - DOI - PMC - PubMed

LinkOut - more resources